GSK's Shingrix skyrockets toward the £1B mark as HIV drugs falter

GlaxoSmithKline’s shingles vaccine Shingrix is growing insanely fast. So fast, in fact, it's on track to surpass £1 billion in sales for its second full year on the market. But another pillar of the British drugmaker’s business—its HIV franchise—is suffering from new competition.